Dioxopromethazine Hydrochloride
CAS number： 13754-56-8
Molecular formula： C17H20N2O2S
molecular weight： 316.41800
Chemical structure：
Producers shown on SFDA
(Record date:08/10/2021）
Producer | Documents | GMP Valid till(based on SFDA) |
Dalian Wonful Pharmaceutical Co., Ltd. | GMP | Valid till May 2020 |
Dandong Yichuang Pharmaceutical Co., Ltd. | GMP | Valid till June 2020 |
Liaoyuan Dikang Pharmaceutical Co., Ltd. | GMP | Valid till February 2022 |
Liaoyuan Baikang Pharmaceutical Co., Ltd. | GMP | Valid till November 2023 |
Shandong Xinyi Pharmaceutical Co., Ltd. | GMP | Valid till January 2019 |
Producers shown on EP
Company owned There are 5 API codes and 25 preparation codes. In 2015, API passed the new national GMP certification. The company focuses on API and advanced intermediate products. The company has passed the audit of many international well-known enterprises. Its products are exported to Italy, Germany, France, South America, North America, India and other countries in the world.
Staff size:50-99 persons
Registered capital:RMB 90 million
Producer:The predecessor of Dandong Yichuang Pharmaceutical Co., Ltd. is the former Dandong pharmaceutical factory. The former Dandong pharmaceutical factory was founded in 1954 and is a large state-owned enterprise. Dandong Yichuang Pharmaceutical Co., Ltd. is a joint-stock company transformed on this basis in December 2003. The registered capital of the company is 7.14 million yuan and has total assets of 460 million yuan. The new plant is located in the Binhai west area of Donggang Economic Development Zone, covering an area of 131 mu with a total investment of nearly 240 million yuan. As of June 2015, it has completed the new national GMP certification of small volume injection, solid oral preparation and synthetic API workshop and obtained the certificate. The company's main product dosage forms officially reached production in 2015. The new plant has formed a production capacity of 240 tons of chemical APIs, 3 billion tablets, 50 million freeze-dried powder injections and 50 million water injections.
Staff size:200-299 persons
Registered capital:RMB 7 million 142 thousand and 857
Producer:Liaoyuan Dikang Pharmaceutical Co., Ltd. covers an area of 78000 square meters, a construction area of 20000 square meters and a total asset of 120 million. The company fully implements GMP management and has five chemical synthesis production lines, one biopharmaceutical production line, one solid preparation production line and one lyophilized powder injection production line. At present, it produces more than ten kinds of chemical synthetic APIs, with an annual production capacity of 2600 tons; It produces more than 60 varieties of tablets, capsules and other proprietary drugs, with an annual output of 4 billion tablets (tablets); 30 million lyophilized powder injections were produced.
Staff size:About 50 persons
Registered capital:RMB 50.26 million
Producer:Liaoyuan Baikang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Sansheng Industrial Co., Ltd. Its predecessor, Liaoyuan No. 1 pharmaceutical factory, was founded in 1958.
After more than 50 years of accumulation and development, the company now has 104 drug production approval numbers, including 20 APIs and 84 preparations. The leading varieties of API are acetaminophen, chlorpipetin hydrochloride, nefopam hydrochloride, procaine hydrochloride, diphenhydramine hydrochloride, famotidine, dioxpromazine hydrochloride and levofloxacin mesylate. The annual output of preparations is more than 2 billion tablets, mainly including chlorpipetin hydrochloride tablets and compound paracetamol diphenhydramine tablets. The company has import and export rights, and its products are mainly exported to India, Hong Kong, Macao, Taiwan and other countries and regions. The company has passed GMP certification and COS certification, and is applying for FDA certification to obtain a pass for products to enter the European and American markets.
Staff size:About 400 persons
Registered capital:RMB 50 million
Producer:Shandong Xinyi Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating manufacturing, sales and R & D, jointly funded by Shanghai Xinyi Pharmaceutical Factory Co., Ltd., a wholly-owned subsidiary of Shanghai Pharmaceutical Group Co., Ltd., Shandong Pingyuan pharmaceutical factory and Dezhou Borun Pharmaceutical Technology Co., Ltd.
Staff size:200-299 persons
Registered capital:RMB 17740.615851 million
For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978
Tel: Cell/WhatsApp/WeChat: +86 18402846978
Email: paulzhang@yinuopharmchem.com
SKYPE